Literature DB >> 15781467

Locating an antagonist in the 5-HT3 receptor binding site using modeling and radioligand binding.

Andrew J Thompson1, Kerry L Price, David C Reeves, S Ling Chan, P-L Chau, Sarah C R Lummis.   

Abstract

We have used a homology model of the extracellular domain of the 5-HT(3) receptor to dock granisetron, a 5-HT(3) receptor antagonist, into the binding site using AUTODOCK. This yielded 13 alternative energetically favorable models. The models fell into 3 groups. In model type A the aromatic rings of granisetron were between Trp-90 and Phe-226 and its azabicyclic ring was between Trp-183 and Tyr-234, in model type B this orientation was reversed, and in model type C the aromatic rings were between Asp-229 and Ser-200 and the azabicyclic ring was between Phe-226 and Asn-128. Residues located no more than 5 A from the docked granisetron were identified for each model; of 26 residues identified, 8 were found to be common to all models, with 18 others being represented in only a subset of the models. To identify which of the docking models best represents the ligand-receptor complex, we substituted each of these 26 residues with alanine and a residue with similar chemical properties. The mutant receptors were expressed in human embryonic kidney (HEK)293 cells and the affinity of granisetron determined using radioligand binding. Mutation of 2 residues (Trp-183 and Glu-129) ablated binding, whereas mutation of 14 other residues caused changes in the [(3)H]granisetron binding affinity in one or both mutant receptors. The data showed that residues both in and close to the binding pocket can affect antagonist binding and overall were found to best support model B.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15781467     DOI: 10.1074/jbc.M413610200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  36 in total

1.  Agonists and antagonists bind to an A-A interface in the heteromeric 5-HT3AB receptor.

Authors:  M Lochner; S C R Lummis
Journal:  Biophys J       Date:  2010-04-21       Impact factor: 4.033

2.  Unbinding pathways of an agonist and an antagonist from the 5-HT3 receptor.

Authors:  A J Thompson; P-L Chau; S L Chan; S C R Lummis
Journal:  Biophys J       Date:  2005-12-30       Impact factor: 4.033

3.  Structure-based 3D-QSAR studies on thiazoles as 5-HT3 receptor antagonists.

Authors:  Li-Ping Zhu; De-Yong Ye; Yun Tang
Journal:  J Mol Model       Date:  2006-09-05       Impact factor: 1.810

4.  A cation-π interaction at a phenylalanine residue in the glycine receptor binding site is conserved for different agonists.

Authors:  Stephan A Pless; Ariele P Hanek; Kerry L Price; Joseph W Lynch; Henry A Lester; Dennis A Dougherty; Sarah C R Lummis
Journal:  Mol Pharmacol       Date:  2011-01-25       Impact factor: 4.436

5.  Mapping spatial relationships between residues in the ligand-binding domain of the 5-HT3 receptor using a molecular ruler.

Authors:  Heather L Nyce; Spencer T Stober; Cameron F Abrams; Michael M White
Journal:  Biophys J       Date:  2010-05-19       Impact factor: 4.033

6.  Defining the roles of Asn-128, Glu-129 and Phe-130 in loop A of the 5-HT3 receptor.

Authors:  Nora L Sullivan; Andrew J Thompson; Kerry L Price; Sarah C R Lummis
Journal:  Mol Membr Biol       Date:  2006 Sep-Oct       Impact factor: 2.857

Review 7.  5-HT3 receptors.

Authors:  A J Thompson; S C R Lummis
Journal:  Curr Pharm Des       Date:  2006       Impact factor: 3.116

8.  Colchicine: a novel positive allosteric modulator of the human 5-hydroxytryptamine3A receptor.

Authors:  A N de Oliveira-Pierce; R Zhang; T K Machu
Journal:  J Pharmacol Exp Ther       Date:  2009-02-02       Impact factor: 4.030

9.  Calcium modulation of 5-HT3 receptor binding and function.

Authors:  Andrew J Thompson; Sarah C R Lummis
Journal:  Neuropharmacology       Date:  2008-07-16       Impact factor: 5.250

Review 10.  The 5-HT3 receptor--the relationship between structure and function.

Authors:  Nicholas M Barnes; Tim G Hales; Sarah C R Lummis; John A Peters
Journal:  Neuropharmacology       Date:  2008-08-12       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.